TY - JOUR JO - Central European Journal of Immunology SN - 1426-3912 VL - 45 IS - 2 PY - 2020 ID - Yalcin2020 TI - Human(ized) monoclonal antibodies in atopic patients – state of the art AB - Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma. AU - Yalcin, Arzu Didem AU - Onbasi, Kevser AU - Uzun, Rusen AU - Herth, Felix AU - Schnabel, Philipp Albert SP - 195 EP - 201 DA - 2020 DO - 10.5114/ceji.2020.97909 UR - http://dx.doi.org/10.5114/ceji.2020.97909 ER -